Climb Bio (CLYM) Non-Current Deferred Tax Liability (2021 - 2025)
Climb Bio (CLYM) reported Non-Current Deferred Tax Liability of -$15000.0 for Q4 2025, down 157.69% on a YoY basis from $26000.0 in Q4 2024, and down 157.69% quarter-over-quarter from $26000.0 in Q4 2024.
Climb Bio (CLYM) Non-Current Deferred Tax Liability (2021 - 2025) Analysis & Trends
Climb Bio has reported Non-Current Deferred Tax Liability for 3 years, with the latest figure at -$15000.0 in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Deferred Tax Liability fell 157.69% year-over-year to -$15000.0; the trailing twelve-month figure through Dec 2025 stood at -$15000.0 (down 157.69% YoY), and the FY2025 full-year result was -$15000.0, down 157.69% from the prior year.
- Non-Current Deferred Tax Liability for Q4 2025 stood at -$15000.0, down from $26000.0 in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $26000.0 in Q4 2024, with the low at -$15000.0 in Q4 2025.
- Historically, Non-Current Deferred Tax Liability has averaged $0.0 across 3 years, with a median of -$11000.0 in 2021.
- The largest YoY upside for Non-Current Deferred Tax Liability was 157.69% in 2025 against a maximum downside of 157.69% in 2025.
- Climb Bio's Non-Current Deferred Tax Liability stood at -$11000.0 in 2021, then jumped by 336.36% to $26000.0 in 2024, then sank by 157.69% to -$15000.0 in 2025.
- The last three Non-Current Deferred Tax Liability figures came in at -$15000.0 (Q4 2025), $26000.0 (Q4 2024), and -$11000.0 (Q4 2021), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Climb Bio | 740.73 Mn | 740.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15,000.00 |
| Dec 31, 2025 | -15,000.00 |
| Dec 31, 2024 | 26,000.00 |
| Dec 31, 2024 | 26,000.00 |
| Dec 31, 2021 | -11,000.00 |
| Dec 31, 2021 | -11,000.00 |